| Identification | Back Directory | [Name]
N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide | [CAS]
2754408-94-9 | [Synonyms]
PF07799933
Claturafenib
N-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide
N-[2-Chloro-3-[(5-chloro-3,4-dihydro-3-methyl-4-oxo-6-quinazolinyl)amino]-4-fluorophenyl]-3-fluoro-1-azetidinesulfonamide | [Molecular Formula]
C18H15Cl2F2N5O3S | [MOL File]
2754408-94-9.mol | [Molecular Weight]
490.31 |
| Chemical Properties | Back Directory | [Boiling point ]
585.0±60.0 °C(Predicted) | [density ]
1.72±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
6.62±0.40(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
Claturafenib ( PF-07799933) is an inhibitor of pan-mutant BRAF. Claturafenib inhibits pERK in HT29 cells with an IC50 value of 1.6 nM[1]. | [References]
[1] Rona Yaeger, et al. A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation. Cancer Discov. 2024 Sep 4;14(9):1599-1611. DOI:10.1158/2159-8290.CD-24-0024 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|